07:00 , Sep 17, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MicroRNA-221 (miR-221); miR-222

Cancer INDICATION: Multiple myeloma (MM) Mouse and patient sample studies suggest inhibiting miR-221 and miR-222 could help treat dexamethasone-resistant MM. Levels of miR-221 and miR-222 were higher in MM cells from patients with dexamethasone-resistant disease...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Company News

Regulus, Sanofi deal

Sanofi and Regulus extended a 2010 deal to discover, develop and commercialize microRNA therapeutics to treat Orphan indications and cancer. Under the extension, Regulus granted Sanofi an exclusive option to develop and commercialize Regulus' preclinical...
08:00 , Nov 10, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer MicroRNA-222 (miR-222); miR-181b Studies in mice suggest inhibiting miR-222 or miR-181b could help treat tamoxifen-resistant breast cancer. In tamoxifen-treated xenograft mice with drug-resistant...
08:00 , Jan 7, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lung cancer; liver cancer MicroRNA-221 (miR-221); miR-222; phosphatase and tensin homolog deleted on chromosome ten (PTEN; MMAC1; TEP1); tissue inhibitor of metalloproteinases 3 (TIMP3); tumor...